The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg

Atherosclerosis

Volumn 200, Issue 1, 2008, Pages 121-125

  Kearns, Amy K ^a   Bilbie, Cherie L ^a   Clarkson, Priscilla M ^b   White, C Michael ^c   Sewright, Kim A ^b   O'Fallon, Kevin S ^b   Gadarla, Mamatha ^a   Thompson, Paul D ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Creatine kinase; Eccentric exercise; High cholesterol; Statin

Indexed keywords

ATORVASTATIN; CREATINE KINASE; CREATINE KINASE MB; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERABILITY; EVENING DOSAGE; EXERCISE; HUMAN; HUMAN EXPERIMENT; LEG MUSCLE; LOW DRUG DOSE; MALE; MUSCLE INJURY; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; WALKING;

ADULT; ANTICHOLESTEREMIC AGENTS; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE; EXERCISE TEST; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PAIN; PYRROLES;

EID: 49749145305     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.12.029     Document Type: Article

References (15)

1. Thompson P.D., Zmuda J.M., Domalik L.J., et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46 (1997) 1206-1210
2. Carter A., Dobridge J., and Hackney A.C. Influence of estrogen on markers of muscle tissue damage following eccentric exercise. Fiziol Cheloveka 27 (2001) 133-137
3. Nosaka K., Clarkson P.M., McGuiggin M.E., and Byrne J.M. Time course of muscle adaptation after high force eccentric exercise. Eur J Appl Physiol Occup Physiol 63 (1991) 70-76
4. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
5. Reust C.S., Curry S.C., and Guidry J.R. Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise. West J Med 154 (1991) 198-200
6. Smit J.W.A., Amelink G.J., de Bruin T.W.A., Bar D.W., and Erkelens D.W. Increased human myoglobin and creating kinase serum levels after standardized exercise during simvastatin treatment. Eur J Clin Invest A31 (1990)
7. Jaweed M., Glennon T., and Dean M. Serum creatine kinase levels in response to combined lovastatin administration and exercise. Clin Res 41 (1993) 600A
8. Medvier G., Pipe A., Davies R., Kennedy S., and Morgan K. Predictive value of baseline creating kinase (CK) in the subsequent response to combined simvastatin administration and exercise. Clin Res 41 (1993) 600A
9. Newman C., Tsai J., Szarek M., Luo D., and Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97 (2006) 61-67
10. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
11. Bruckert E., Hayem G., Dejager S., Yau C., and Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 19 (2005) 403-414
12. Thompson P.D., Gadaleta P.A., Yurgalevitch S., Cullinane E., and Herbert P.N. Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism 40 (1991) 1333-1336
13. Clarkson P.M., Hoffman E.P., Zambraski E., et al. ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol 99 (2005) 564-569
14. Ruano G., Thompson P.D., Windemuth A., et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 6 (2005) 865-872
15. Vladutiu G.D., Simmons Z., Isackson P.J., et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34 (2006) 153-162